search
Back to results

Financial Incentives And Nurse Coaching to Enhance Diabetes Outcomes (FINANCE-DM)-1 (FINANCE-DM)

Primary Purpose

Type 2 Diabetes

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
FINANCE-DM
Active Comparator
Sponsored by
Medical College of Wisconsin
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Type 2 Diabetes

Eligibility Criteria

21 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age >=21 years;
  2. Clinical diagnosis of T2DM and HbA1c >=8% at the screening visit;
  3. Self-identified as White, AA or HA;
  4. Subject must be willing to use the FORA monitoring system for 12 months;
  5. Subjects must have access to a landline, Ethernet or cellphone for FORA data uploads for the study period; and 6) Ability to communicate in English.

Exclusion Criteria:

  1. Mental confusion on interview suggesting significant dementia;
  2. Participation in other diabetes clinical trials;
  3. Alcohol or drug abuse/dependency;
  4. Active psychosis or acute mental disorder; and
  5. Life expectancy <18 months.

Sites / Locations

  • Medical College of WisconsinRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

FINANCE-DM Intervention

TIDES Intervention

Arm Description

The FINANCE-DM intervention is comprised of: 1) nurse education, 2) home telemonitoring, and 3) structured financial incentives.

Patients randomized to the active comparator group will be assigned the FORA 2-in-1 Telehealth System. A nurse educator will review the glucose and BP readings and use them to tailor and reinforce behavior change.

Outcomes

Primary Outcome Measures

Glycemic control (HbA1c)
Blood specimens (10cc of blood) will be obtained by trained phlebotomists or nurse for HbA1c.
Resource Utilization and Cost
Previously validated questions on resource utilization will be administered. The questionnaires capture information on hospitalizations, physician/professional visits, and medications.

Secondary Outcome Measures

LDL-Cholesterol
About 10cc of blood will be drawn by trained phlebotomists and sent to the lab for LDL-Cholesterol.
Quality of Life as measured by SF-12
The SF-12 (Ware 1996) is a valid and reliable instrument to measure functional status and reproduces 90% of the variance in PCS-36 and MCS-36 scores.
Systolic and Diastolic Blood Pressure
Blood pressure readings will be obtained using automated BP monitors (OMRON IntelliSenseTM HEM-907XL). The device will be programmed to take 3 readings at 2-minute intervals, and give an average of the 3 BP readings.
Self-Care Behavior
Behavioral skills will be assessed with the Summary of Diabetes Self-Care Activities (SDSCA) scale (Toobert 2000), a brief, validated questionnaire of diabetes self-care. .
Self-Care Behavior Brooks Medication Adherence Scale (BMAS)
Medication Adherence will be measured with the 6-item validated self-report Brooks Medication Adherence Scale (BMAS) (Brooks 1994). Each of 6 items measures a specific medication-taking behavior.

Full Information

First Posted
November 26, 2019
Last Updated
January 30, 2023
Sponsor
Medical College of Wisconsin
search

1. Study Identification

Unique Protocol Identification Number
NCT04203173
Brief Title
Financial Incentives And Nurse Coaching to Enhance Diabetes Outcomes (FINANCE-DM)-1
Acronym
FINANCE-DM
Official Title
Financial Incentives And Nurse Coaching to Enhance Diabetes Outcomes - FINANCE-DM
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 1, 2019 (Actual)
Primary Completion Date
March 31, 2024 (Anticipated)
Study Completion Date
March 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Medical College of Wisconsin

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The objective of this protocol is to answer the questions: 1) Are financial incentives layered upon nurse education and home telemonitoring superior to nurse education and home telemonitoring alone in improving metabolic control long term? 2) Are the effects of financial incentives on metabolic control sustained once the incentives are withdrawn? and 3) Are financial incentives efficacious within and consistent across racial/ethnic groups? This study provides a unique opportunity to address these gaps in the literature. Investigators propose a randomized controlled trial to test the efficacy of a Financial Incentives And Nurse Coaching to Enhance Diabetes Outcomes (FINANCE-DM) intervention comprised of: 1) nurse education, 2) home telemonitoring, and 3) structured financial incentives; compared to an active control group (nurse education and home telemonitoring alone). The study also will evaluate whether intervention effects are sustained 6 months after the financial incentives are withdrawn (i.e. 18 months post randomization); and whether the intervention is differentially efficacious across racial/ethnic groups.
Detailed Description
Study Overview. The overarching aim of this proposal is to test the efficacy of structured financial incentives intervention (FINANCE-DM) comprised of: 1) nurse education, 2) home telemonitoring, and 3) structured financial incentives; compared to an active control group (nurse education and home telemonitoring alone) on glycemic control. The study also will evaluate whether intervention effects are sustained 6 months after the financial incentives are withdrawn (i.e. 18 months post randomization); and whether the intervention is differentially efficacious across racial/ethnic groups. Equal number of patients from three racial/ethnic groups (150 Whites, 150 AAs and 150 HAs, total sample of 450) will be randomized to FINANCE-DM intervention (n=225) or an active comparator group (n=225), so that within each racial/ethnic group, half (75 patients) will be randomized to the FINANCE-DM intervention group and the other half (75 patients) will be randomized to the active comparator group. Primary aims are to test overall efficacy across combined racial/ethnic groups; efficacy within racial/ethnic groups and cost effectiveness for the primary endpoint (glycemic control). Secondary aim is to test efficacy on secondary endpoints including BP, LDL, QOL and self-care behaviors. Each patient will be followed for 12 months (long-term effect) and 18 months (sustainability effect), with study visits at baseline, 3, 6, 9, 12 and 18 months. The FINANCE-DM intervention is comprised of: 1) nurse education, 2) home telemonitoring, and 3) structured financial incentives. The active comparator group will receive the same nurse education and home telemonitoring intervention as the FINANCE-DM group, on the same schedule, and for the same duration . The only difference is that participants will not receive structured financial incentives.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
450 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
FINANCE-DM Intervention
Arm Type
Experimental
Arm Description
The FINANCE-DM intervention is comprised of: 1) nurse education, 2) home telemonitoring, and 3) structured financial incentives.
Arm Title
TIDES Intervention
Arm Type
Active Comparator
Arm Description
Patients randomized to the active comparator group will be assigned the FORA 2-in-1 Telehealth System. A nurse educator will review the glucose and BP readings and use them to tailor and reinforce behavior change.
Intervention Type
Behavioral
Intervention Name(s)
FINANCE-DM
Intervention Description
The FINANCE-DM intervention is comprised of: 1) nurse education, 2) home telemonitoring, and 3) structured financial incentives. Patients randomized to FINANCE-DM will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. BG and BP will be measured daily and results will be uploaded to a secure server. A nurse educator will review the glucose and BP readings and use them to tailor and reinforce behavior change during weekly telephone-delivered diabetes education and skills training session. Participants will also receive financial rewards for: 1) uploading glucose measurements; 2) participating in telephone delivered educational sessions; and 3) absolute percentage drops in HbA1c from baseline at each 3-month follow-up intervals.
Intervention Type
Behavioral
Intervention Name(s)
Active Comparator
Intervention Description
Patients randomized to the active comparator group will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. BG and BP will be measured daily and results will be uploaded to a secure server. A nurse educator will review the glucose and BP readings and use them to tailor and reinforce behavior change during weekly telephone-delivered diabetes education and skills training session.
Primary Outcome Measure Information:
Title
Glycemic control (HbA1c)
Description
Blood specimens (10cc of blood) will be obtained by trained phlebotomists or nurse for HbA1c.
Time Frame
Change from baseline HbA1c at 12 months post intervention follow-ups
Title
Resource Utilization and Cost
Description
Previously validated questions on resource utilization will be administered. The questionnaires capture information on hospitalizations, physician/professional visits, and medications.
Time Frame
Change from baseline resource utilization and cost at at 12 months post-intervention follow-ups
Secondary Outcome Measure Information:
Title
LDL-Cholesterol
Description
About 10cc of blood will be drawn by trained phlebotomists and sent to the lab for LDL-Cholesterol.
Time Frame
Change from baseline cholesterol at at 12 months post intervention follow-ups
Title
Quality of Life as measured by SF-12
Description
The SF-12 (Ware 1996) is a valid and reliable instrument to measure functional status and reproduces 90% of the variance in PCS-36 and MCS-36 scores.
Time Frame
Change from baseline quality of life measure at at 12 months post intervention follow-ups
Title
Systolic and Diastolic Blood Pressure
Description
Blood pressure readings will be obtained using automated BP monitors (OMRON IntelliSenseTM HEM-907XL). The device will be programmed to take 3 readings at 2-minute intervals, and give an average of the 3 BP readings.
Time Frame
Change from baseline blood pressure at at 12 months post intervention follow-ups
Title
Self-Care Behavior
Description
Behavioral skills will be assessed with the Summary of Diabetes Self-Care Activities (SDSCA) scale (Toobert 2000), a brief, validated questionnaire of diabetes self-care. .
Time Frame
Change from baseline self-care at at 12 months post intervention follow-ups
Title
Self-Care Behavior Brooks Medication Adherence Scale (BMAS)
Description
Medication Adherence will be measured with the 6-item validated self-report Brooks Medication Adherence Scale (BMAS) (Brooks 1994). Each of 6 items measures a specific medication-taking behavior.
Time Frame
Change from baseline self-care at at 12 months post intervention follow-ups

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age >=21 years; Clinical diagnosis of T2DM and HbA1c >=8% at the screening visit; Self-identified as White, AA or HA; Subject must be willing to use the FORA monitoring system for 12 months; Subjects must have access to a landline, Ethernet or cellphone for FORA data uploads for the study period; and 6) Ability to communicate in English. Exclusion Criteria: Mental confusion on interview suggesting significant dementia; Participation in other diabetes clinical trials; Alcohol or drug abuse/dependency; Active psychosis or acute mental disorder; and Life expectancy <18 months.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Elise A Mosley-Johnson, MPH
Phone
414-955-8810
Email
emosley@mcw.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Leonard E Egede, MD, MS
Organizational Affiliation
Medical College of Wisconsin
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medical College of Wisconsin
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53226
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elise Mosley-Johnson, MPH
Phone
414-955-8810
Email
emosley@mcw.edu

12. IPD Sharing Statement

Citations:
PubMed Identifier
33371048
Citation
Egede LE, Walker R, Williams JS, Knapp R, Dismuke CE, Davidson T, Campbell JA. Financial Incentives and Nurse Coaching to Enhance Diabetes Outcomes (FINANCE-DM): a trial protocol. BMJ Open. 2020 Dec 22;10(12):e043760. doi: 10.1136/bmjopen-2020-043760.
Results Reference
background
Links:
URL
https://bmjopen.bmj.com/content/bmjopen/10/12/e043760.full.pdf
Description
PDF of study protocol paper

Learn more about this trial

Financial Incentives And Nurse Coaching to Enhance Diabetes Outcomes (FINANCE-DM)-1

We'll reach out to this number within 24 hrs